Core Laboratories N.V.
NYSE:CLBOil & Gas Equipment & Services
+$0.12 today
- Market cap
- $387.21M
- Beta
- 0.99
- P/E (TTM)
- 18.3
- EPS (TTM)
- $0.63
- Dividend yield
- 0.35%
Volume 0.52M
Average 0.49M
CLB Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Core Laboratories N.V.NYSE: CLB
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows in line with its trailing trend
Q1 FY2026 selling, general & admin of $14.72M rose 7.8% year over year, behind the +9.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 56.1% from the prior quarter. Over 3 fiscal years it compounded at +5.1% a year.
Context
- Selling, general & admin amounted to 8.4% of revenue in FY2025, up 1.0 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $41.37M (-6.5%) for the fiscal year ending Dec 2026, a slowdown from the +14.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $14.72M+56.1% QoQ
- Last fiscal yearDec 2025
- $44.23M+14.6% YoY
- LTMMar 2026
- $45.3M+9.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +7.8% | -2.1% | -9.9 pp |
| 1 year | +14.6% | -6.5% | -21.1 pp |
| 3-year CAGR | +5.1% | +0.5% | -4.5 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 44.23M USD
- Year-over-year change
- +14.6%
- 4-year CAGR
- +0.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 44.23M | +14.6% |
| FY2024 | 2024-12-31 | 38.59M | -0.8% |
| FY2023 | 2023-12-31 | 38.89M | +2.0% |
| FY2022 | 2022-12-31 | 38.12M | -13.7% |
| FY2021 | 2021-12-31 | 44.17M | — |
Selling, General & Admin vs competitors
How CLB compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +9.6% is the 7th highest of 10, against a peer median of +20.2%.
- Selling, general & admin amounts to 8.6% of revenue for CLB, versus a peer median of 6.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $307.84M USD | +20.2% | +10.1% | 9.5% | |
| LTM Mar 2026 | $201.92M USD | +55.7% | — | 15886.3% | |
| LTM Mar 2026 | CA$126.42M CAD | +8.0% | -14.2% | 6.7% | |
| LTM Mar 2026 | $93.7M USD | +96.4% | -11.8% | 2.6% | |
| LTM Mar 2026 | $53.1M USD | +13.2% | +11.1% | 5.1% | |
| LTM Mar 2026 | $45.3M USD | +9.6% | +5.1% | 8.6% | |
| LTM Mar 2026 | $32.63M USD | +27.3% | +29.7% | 7.2% | |
| LTM Mar 2026 | $25.98M USD | -16.6% | -17.3% | 3.4% | |
| LTM Mar 2026 | $23.84M USD | +66.5% | +135.4% | 6.7% | |
| LTM Mar 2026 | $18.3M USD | -53.4% | +56.2% | 6.6% | |
| Peer median (excluding CLB) | — | +20.2% | +10.6% | 6.7% | |
Competitors are the stored peer set for CLB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 470.25M | 489.74M | 509.79M | 523.85M | 526.52M |
| Cost of Revenue | 386.41M | 410.82M | 415.74M | 435.48M | 432.24M |
| Gross Profit | 83.84M | 78.92M | 94.05M | 88.37M | 94.28M |
| Gross Margin | 17.8% | 16.1% | 18.4% | 16.9% | 17.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 44.17M | 38.12M | 38.89M | 38.59M | 44.23M |
| Operating Expenses | 38.58M | 37.4M | 39.41M | 29.82M | 43.8M |
| Depreciation & Amortization | 18.52M | 17.16M | 15.78M | 14.95M | 14.65M |
| EBITDA | 63.78M | 58.69M | 70.42M | 73.51M | 71.12M |
| EBITDA Margin | 13.6% | 12.0% | 13.8% | 14.0% | 13.5% |
| Operating Income | 45.26M | 41.52M | 54.64M | 58.56M | 50.49M |
| Operating Margin | 9.6% | 8.5% | 10.7% | 11.2% | 9.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 9.15M | 11.57M | 13.43M | 12.37M | 10.57M |
| Other Income / Expenses | (9.15M) | (11.57M) | (13.43M) | (12.37M) | (4.59M) |
| Income Before Tax | 36.11M | 29.95M | 41.21M | 46.19M | 45.9M |
| Pre-Tax Margin | 7.7% | 6.1% | 8.1% | 8.8% | 8.7% |
| Income Tax Expense | 15.89M | 10.3M | 4.19M | 14.03M | 15.51M |
| Net Income | 19.73M | 19.45M | 36.68M | 31.4M | 29.67M |
| Net Margin | 4.2% | 4.0% | 7.2% | 6.0% | 5.6% |
| EPS (Basic) | 0.43 | 0.42 | 0.79 | 0.67 | 0.68 |
| EPS (Diluted) | 0.42 | 0.42 | 0.77 | 0.66 | 0.68 |
| Weighted Avg Shares | 46.01M | 46.33M | 46.68M | 46.9M | 46.5M |
| Weighted Avg Shares (Diluted) | 46.69M | 46.81M | 47.52M | 47.69M | 46.5M |
Core Laboratories N.V.
NYSE:CLB
Intrinsic Alpha fair value
Locked
Current Price
$8.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.